Posted on 29/10/2009 in Pharmaceutical Company Financials Kyowa Hakko Kirin has stated that its pharmaceuticals business continues to perform strongly, as the firm revealed its financial result for the third quarter of 2009.
The organisation posted consolidated net sales of 194.3 billion yen (1.3 billion pounds) for the period, which marks a decrease of 21.5 per cent compared to the same time in 2008.
Its operating income fell by 28.7 per cent to 20.7 billion yen, while net income underwent an increase of 2.5 billion yen to 10.8 billion yen - a rise of 30.5 per cent.
"Based on our strong financial foundations, we will continue to evolve from our foundations in biotechnology to become a world-class research and development-based life sciences group focused on pharmaceuticals," explained president and chief executive officer of the firm Yuzuru Matsuda.
Kyowa Hakko Kirin was established in 2008 following the merging of Kyowa Hakko and Kirin Pharma, which were formed in 1944 and 1885 respectively.
Other news stories from 29/10/2009
Read more in the Zenopa News Archive
How this news is generated
|
